-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the CARD study, cabazitaxel (kabatasai) significantly extended the progression-free survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors.
is now a summary of the quality of life prognossing of card studies.
CARD was a randomized, open-label Phase 4 study conducted at 62 clinical centres in 13 European countries, in which patients diagnosed with metastatic desopathic prostate cancer over the age of 18 were randomly assigned to the Kabatha group (25 mg/m2, static drops) at 1:1. , once every 3 weeks; strong pine, 10 mg/day and granulocyte set stimulation factor) vs Abitron group (1000 mg/day plus strong pine 5 mg.2/day) or Enrugrumam group (160 mg/day, oral).
end point is progress-free survival.
November 17, 2015 - November 28, 2018, a total of 303 patients were screened, 255 of whom were randomly assigned to the Kabata group (n-129) or the abitron/ensergide group (n-126).
followed for 9.2 months (range 5.6-13.1 months).
51 (46%) of the 111 patients in the Kabata group and 21 (19%) of the 109 patients in the abitron/enrugluamine group received pain relief.
the progression of pain symptoms in the kabata group and the mid-term time for bone-injury symptoms were not reached, and the abitron/ensergide group was 8.5 months (4.9-failed; risk ratio was 0.55, 95% CI 0.3) 2-0.97; p-0.050) and 16.7 months (10.8-failed; 0.59,95% CI 0.35-1.01, p-0.050).
the total FACT-P score of the Kabata group deteriorated by 14.8 months, while the Abitron/Enserooamine group had a medium time of 8.9 months (HR 0.72, 95% CI 0.44-1.20, p=0.21). The baseline value change of the EQ-5D-5L utility index score of the
Kabata group was also significantly better than that of the Abitron/Enruguruamine group, but there was no difference in the baseline change of the EQ-5D-5L visual simulation scale between the treatment groups.
study showed that kabathal improved pain relief, delayed pain progression, and the time of skeletal symptoms, as well as the EQ-5D-5L utility index score, which does not degrade quality of life compared to the use of second-generation androgen signal target inhibitors.
.
